EA
ABBV icon

Evolution Advisers’s AbbVie ABBV Stock Holding History

Evolution Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
+5
New +$1.08K ﹤0.01% 171
2025
Q1 		– Sell
-8
Closed -$1K – 152
2024
Q4 		$1K Hold
8
– – ﹤0.01% 148
2024
Q3 		$1K Hold
8
– – ﹤0.01% 155
2024
Q2 		$1K Buy
+8
New +$1.32K ﹤0.01% 147

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Evolution Advisers's ABBV Position: Q2 2026 in Review

Evolution Advisers opened a new position in AbbVie (ABBV) in Q2 2026: 5 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #171 among its holdings. This is a return to the name: Evolution Advisers previously reported a position in ABBV as recently as Q4 2024.

Evolution Advisers first reported a position in ABBV in Q2 2024 and has held it in 4 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Evolution Advisers held 5 shares of AbbVie worth $1K as of Q2 2026.
  • AbbVie was a new Evolution Advisers position in Q2 2026.
  • AbbVie made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #171 holding.
  • Evolution Advisers first reported a position in AbbVie in Q2 2024 and has held it in 4 quarters since.
  • 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.